Pelvic Inflammatory Disease: Pelvic inflammatory disease (PID) is an acute or chronic inflammation in the pelvic cavity. It is most commonly caused by sexually transmitted diseases, including chlamydia and gonorrhea that have ascended into the uterus, fallopian tubes, or ovaries as a result of intercourse or childbirth, or of surgical procedures, including insertion of IUDs or abortion. PID may be either symptomatic or asymptomatic. It may cause infertility and it may raise the risk of ectopic pregnancy. PID is a disease associated with HIV infection.
Female pelvic inflammatory disorders in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
N14_FEMPELINFINOTH
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
138 |
4. Check minimum number of eventsNone |
138 |
5. Include endpointsNone |
138 |
6. Filter based on genotype QC (FinnGen only) |
138 |
Control definitions (FinnGen only)
- Control exclude
- N14_FEMALEGENINF
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Female pelvic inflammatory disorders in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Inflammatory diseases of female pelvic organs
- Genitourinary diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1114 | 1114 | - |
| Only index persons | 1099 | 1099 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | - |
| Only index persons | 0.04 | 0.04 | - |
| Median age at first event (years) | |||
| Whole population | - | 23.59 | - |
| Only index persons | - | 23.53 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 138 | 138 | - |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | - |
| Median age at first event (years) | 24.91 | 24.91 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 127
- Matched controls
- 1269
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N74.4*A56.1
ICD-10 Finland
Female chlamydial pelvic inflammatory disease
+∞
132.6
103
*
N73.9
ICD-10 Finland
Female pelvic inflammatory disease, unspecified
153.1
33.5
34
*
A56.1
ICD-10 Finland
Chlamydial infection of pelviperitoneum and other genitourinary organs
221.3
19.1
19
*
P01AB01
ATC
metronidazole; oral, rectal
5.7
18.7
87
352
O04.9
ICD-10 Finland
Medical abortion, complete or unspecified, without complication
5.7
15.5
52
137
N71.0
ICD-10 Finland
Acute inflammatory disease of uterus
21.3
13.9
20
11
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
4.1
12.9
80
373
N70.0
ICD-10 Finland
Acute salpingitis and oophoritis
+∞
12.7
12
*
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
4.1
12.7
71
301
J01AA02
ATC
doxycycline; systemic
4.9
11.5
109
704
N70.1
ICD-10 Finland
Chronic salpingitis and oophoritis
+∞
10.6
10
*
N74.4
ICD-10 Finland
Female chlamydial pelvic inflammatory disease
+∞
9.5
9
*
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
3.1
8.8
77
418
N76.0
ICD-10 Finland
Acute vaginitis
5.3
8.7
27
61
N71.9
ICD-10 Finland
Inflammatory disease of uterus, unspecified
21.9
8.6
12
6
R51.80
ICD-10 Finland
Headache
3.8
8.6
40
136
N02AX02
ATC
tramadol; systemic, rectal
3.1
7.6
52
233
N73.6
ICD-10 Finland
Female pelvic peritoneal adhesions
+∞
7.4
7
*
LC2AE
NOMESCO Finland
Ultrasound examination of uterus and parametria
3.5
7.1
37
134
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
3.4
6.9
36
131
J01DB01
ATC
cefalexin; oral
4.1
6.8
115
892
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
3.3
6.8
38
147
N83.2
ICD-10 Finland
Other and unspecified ovarian cysts
3.7
6.6
30
99
M77.1
ICD-10 Finland
Lateral epicondylitis
4.5
6.4
22
56
N70.9
ICD-10 Finland
Salpingitis and oophoritis, unspecified
+∞
6.3
6
*
M03BX02
ATC
tizanidine; oral
2.7
6.2
90
604
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
3.6
6.2
28
92
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
55
247
3.04
8.84
2.1
1.9
48.2
54.2
u/l
1.13
47
232
79
440
2.86
8.43
3.6
2.2
—
—
—
0
0
42
182
2.88
6.99
3.0
2.3
2787.7
5545.4
u/l
0.40
16
86
70
397
2.55
6.78
3.4
2.0
—
—
—
0
0
75
440
2.54
6.75
3.1
4.7
8.3
9.0
umol/l
0.46
67
413
47
236
2.50
5.72
2.0
2.2
7.1
13.3
ng/l
2.15
13
74
51
294
2.17
4.34
3.1
2.6
—
—
—
0
0
127
1064
3.43
4.12
7.9
6.8
3.9
3.9
mmol/l
0.11
121
1016
51
300
2.11
4.08
2.2
1.7
—
—
—
0
0
32
156
2.37
4.03
1.4
1.5
1.4
1.3
%
0.69
26
140
41
231
2.10
3.62
1.8
1.6
—
—
—
0
0
80
574
1.94
3.52
3.9
2.9
0.0
0.0
estimate
0.00
20
118
7
10
7.30
3.40
1.0
1.3
—
—
—
0
0
103
812
2.06
3.37
3.2
2.4
62.5
27.8
u/l
0.88
96
784
79
570
1.90
3.36
5.2
4.0
0.0
0.0
estimate
0.00
21
120
40
233
2.01
3.19
2.5
2.3
0.4
0.3
e6/l
0.14
29
169
116
977
2.17
2.88
4.5
4.6
14.4
14.2
pmol/l
0.47
110
928
78
581
1.79
2.81
3.9
3.0
0.0
0.0
estimate
0.00
22
116
48
310
1.84
2.78
4.1
3.1
0.0
0.0
estimate
0.00
20
119
74
554
1.72
2.53
3.2
3.4
6.3
6.1
mmol/l
0.38
64
464
5
8
6.43
2.39
3.4
1.9
—
—
—
0
0
5
8
6.43
2.39
1.0
1.4
—
—
—
0
0
24
129
2.04
2.35
1.8
1.6
—
—
—
0
0
92
741
1.72
2.33
5.0
5.7
70.1
70.0
u/l
0.01
81
699
40
257
1.78
2.31
1.7
1.6
—
—
—
0
0
14
60
2.48
2.30
2.5
2.5
—
—
—
0
0
5
9
5.71
2.23
1.0
1.2
—
—
—
0
0
5
9
5.71
2.23
1.0
1.2
—
—
—
0
0
5
9
5.71
2.23
1.0
1.2
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
9
5.71
2.23
5.0
1.3
100.2
136.0
%
—
5
9
62
455
1.66
2.20
3.8
2.8
—
—
—
0
0
5
10
5.14
2.09
1.0
1.2
—
—
—
0
0
5
10
5.14
2.09
1.0
1.2
—
—
—
0
0
5
10
5.14
2.09
1.0
1.2
—
—
—
0
0
6
15
4.13
2.06
2.0
1.4
—
—
—
0
0
116
1015
1.90
2.03
7.2
6.5
99.5
98.7
ml/min/173m2
0.16
94
785
129
1190
2.29
1.78
7.7
7.1
21.2
22.5
u/l
0.57
122
1156
96
811
1.60
1.76
3.5
3.2
7.8
7.8
mm/h
0.01
87
769
58
439
1.55
1.72
1.9
1.5
—
—
—
0
0
46
333
1.57
1.64
1.3
1.3
0.6
1.2
u/ml
0.97
16
92
124
1130
1.96
1.60
5.2
5.1
1.5
1.6
mu/l
1.15
115
1080
113
1006
1.68
1.54
4.0
3.0
5.4
5.5
mmol/l
0.51
102
951
58
449
1.50
1.51
1.8
1.7
—
—
—
0
0
16
88
1.93
1.49
1.6
1.4
—
—
—
0
0
5
16
3.20
1.45
1.2
1.1
—
—
—
0
0
20
121
1.76
1.40
2.0
2.1
2.3
5.2
e6/l
—
8
62
5
17
3.01
1.37
1.0
1.2
—
—
—
0
0
5
17
3.01
1.37
1.0
1.1
—
—
—
0
0
117
1062
1.67
1.34
3.2
2.9
4.8
4.7
mmol/l
0.58
110
1022
112
1007
1.60
1.32
2.8
2.7
1.2
1.1
mmol/l
0.31
106
968
12
63
1.99
1.27
1.7
1.5
—
—
—
0
0
21
134
1.67
1.23
1.7
1.9
0.9
1.0
e6/l
—
9
76
6
26
2.37
1.20
4.0
1.8
12.8
13.5
%
—
6
26
16
96
1.75
1.16
1.1
1.3
—
—
—
0
0
115
1056
1.53
1.06
3.2
2.9
1.5
1.5
mmol/l
0.61
107
1015
9
47
1.98
1.04
1.2
1.4
—
—
—
0
0
99
885
1.42
1.04
4.3
3.5
37.0
36.5
mmol/mol
0.21
91
852
18
116
1.63
1.03
1.4
1.6
—
—
—
0
0
13
77
1.76
0.99
2.3
4.0
—
—
—
0
0
124
1164
1.64
0.96
11.3
8.2
20.2
16.8
mg/l
0.60
109
861
6
28
2.19
0.92
1.0
1.1
—
—
—
0
0
35
268
1.41
0.92
1.7
1.7
0.4
0.7
mg/l
3.15
27
194
115
1065
1.48
0.92
3.4
3.0
2.9
2.8
mmol/l
0.32
107
1021
70
600
1.34
0.91
3.7
3.7
—
—
—
0
0
41
324
1.38
0.90
2.8
4.3
1.2
1.2
mmol/l
1.33
34
303
37
291
1.37
0.83
1.9
1.9
2.7
2.6
mg/l
0.06
31
258
7
121
0.56
0.82
1.7
1.5
—
—
—
0
0
6
33
1.85
0.80
4.2
2.9
1.4
-0.5
mmol/l
—
6
23
7
39
1.84
0.73
1.3
2.1
—
—
—
0
0
13
85
1.58
0.72
1.6
1.5
—
—
—
0
0
27
207
1.38
0.71
1.4
1.3
21.1
22.1
nmol/l
0.11
22
189
5
27
1.88
0.69
1.2
1.1
—
—
—
0
0
42
349
1.29
0.65
1.5
1.7
96.4
95.2
pmol/l
0.06
23
201
30
239
1.33
0.62
1.4
1.3
9.5
36.3
iu/ml
—
8
62
25
194
1.35
0.61
1.2
1.5
—
—
—
0
0
6
35
1.75
0.58
5.5
2.7
—
—
—
0
0
11
73
1.55
0.58
1.2
1.3
3.3
2.9
ug/l
0.17
11
68
39
326
1.27
0.57
3.4
3.6
37.0
37.6
g/l
0.29
33
308
6
37
1.65
0.56
1.2
2.1
—
—
—
0
0
6
37
1.65
0.56
5.8
1.8
116.2
147.5
%
—
6
37
11
75
1.51
0.52
1.3
1.4
—
—
—
0
0
11
75
1.51
0.52
1.2
1.4
—
—
—
0
0
6
40
1.52
0.52
1.7
1.3
—
—
—
0
0
43
370
1.24
0.49
3.4
5.1
1.2
1.2
mmol/l
1.24
34
322
11
77
1.47
0.47
4.8
4.0
1.0
1.0
mmol/l
0.03
11
71
35
296
1.24
0.47
2.3
2.6
2.4
2.3
mmol/l
0.37
30
271
11
151
0.70
0.46
1.5
1.6
—
—
—
0
0
71
648
1.20
0.45
3.8
7.3
4.6
3.9
e9/l
1.81
64
571
118
1132
1.29
0.44
4.8
4.2
—
—
—
0
0
8
55
1.48
0.44
1.1
1.7
—
—
—
0
0
5
31
1.64
0.43
1.2
1.4
—
—
—
0
0
8
57
1.43
0.43
1.4
1.6
0.4
0.5
nmol/l
—
8
47
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
29
246
1.23
0.38
1.5
1.5
1.8
1.3
mmol/l
0.41
24
222
22
181
1.26
0.37
1.1
1.4
—
—
—
0
0
22
181
1.26
0.37
1.1
1.4
—
—
—
0
0
51
459
1.18
0.36
2.0
2.2
72.2
72.2
nmol/l
0.00
46
439
6
42
1.45
0.36
1.0
1.5
—
—
—
0
0
22
182
1.25
0.36
1.1
1.4
—
—
—
0
0
22
182
1.25
0.36
1.1
1.4
—
—
—
0
0
6
46
1.32
0.33
1.0
1.0
—
9.9
—
0
9
7
53
1.34
0.31
1.7
1.5
—
—
—
0
0
28
242
1.20
0.31
1.3
1.3
1.0
8.0
u/ml
—
9
106
11
87
1.29
0.25
1.0
1.0
—
—
—
0
0
5
41
1.23
0.22
1.6
1.1
—
—
—
0
0
5
42
1.20
0.21
1.0
2.0
6.0
5.6
kpa
—
5
42
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
3.8
—
15.0
—
0
12
15
172
0.86
0.17
1.9
1.4
—
—
—
0
0
5
45
1.12
0.10
1.0
1.1
—
—
—
0
0
5
45
1.12
0.10
1.0
1.1
—
—
—
0
0
9
83
1.09
0.07
2.0
1.7
5.7
2.7
mg/l
—
9
56
34
327
1.05
0.05
1.4
1.5
—
—
—
0
0
12
130
0.92
0.05
2.0
1.8
—
—
—
0
0
17
167
1.02
0.00
1.2
1.3
334.7
158.6
iu/ml
—
5
70
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
23.3
—
0
7
0
5
0.00
0.00
0.0
1.8
—
12.1
—
0
5
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
6.1
—
0
5
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
22
220
1.00
0.00
1.5
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
5
58
0.86
0.00
1.6
2.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint N14_FEMPELINFINOTH and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have N14_FEMPELINFINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: N14_FEMPELINFINOTH – Female pelvic inflammatory disorders in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data